| Thyroid irAE (N = 58) | No thyroid irAE (N = 127) | P value |
---|---|---|---|
Age (years) a | 66.7 ± 11.1 | 64.1 ± 11.2 | 0.140 |
Male, n (%) | 44 (75.9%) | 91 (71.7%) | 0.675 |
BMI (kg/m2) | 23.2 ± 2.9 | 22.2 ± 4.0 | 0.060 |
T4 replacement before ICI treatment | 4 (6.9%) | 4 (3.1%) | 0.440 |
Underlying malignancy, n (%) | Â | Â | 0.238 |
 lung | 40 (69.0%) | 72 (56.7%) |  |
 melanoma | 3 (5.2%) | 19 (15.0%) |  |
 urothelial cancer | 2 (3.4%) | 5 (3.9%) |  |
 breast | 0 (0%) | 1 (0.8%) |  |
 colon | 0 (0%) | 1 (0.8%) |  |
 esophagus | 3 (5.2%) | 0 (0.0%) |  |
 HCC | 1 (1.7%) | 3 (2.4%) |  |
 jejunum | 0 (0%) | 1 (0.8%) |  |
 mesothelioma | 1 (1.7%) | 4 (3.1%) |  |
 head and neck cancer | 1 (1.7%) | 8 (6.3%) |  |
 ovary | 0 (0%) | 1 (0.8%) |  |
 pancreas | 1 (1.7%) | 0 (0.0%) |  |
 renal | 2 (3.4%) | 2 (1.6%) |  |
 skin | 0 (0%) | 1 (0.8%) |  |
 stomach | 4 (6.9%) | 8 (6.3%) |  |
 thymoma | 0 (0%) | 1 (0.8%) |  |
Immune check point inhibitor, n (%) | Â | Â | 0.196 |
 pembrolizumab | 37 (63.8%) | 63 (49.6%) |  |
 nivolumab | 16 (27.6%) | 50 (39.4%) |  |
 atezolizumab | 7 (8.6%) | 14 (11.0%) |  |
Death, n (%) | 19 (32.8%) | 64 (50.4%) | 0.038 |
Treatment duration b (month) | 8.1 ± 8.0 | 4.0 ± 6.8 |  < 0.001 |
Period from initiation of ICI treatment to death (month) | 14.4 ± 10.9 | 9.7 ± 10 .0 | 0.004 |